Magenta Therapeutics Added to Russell 2000 and 3000 Indexes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 24, 2018--Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the company has been added to the Russell 2000 and 3000 indexes following the Russell U.S. Indexes’ quarterly update.
The Russell 3000 index includes the 3,000 largest U.S. companies by market capitalization. Membership in the Russell 3000 ® Index means automatic inclusion in the large-cap Russell 1000 ® Index or small-cap Russell 2000 ® Index as well as the appropriate growth- and value-style indexes. Russell U.S. Indexes are part of FTSE Russell, a leading global index provider, which determines membership for its Russell U.S. Indexes primarily by objective, market-capitalization rankings and style attributes.
Russell U.S. Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes.
For more information on the Russell Indexes, please visit the “Russell Reconstitution” section on the FTSE Russell website at www.ftserussell.com.
About Magenta Therapeutics
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing an integrated portfolio of therapeutics focused on critical areas of unmet need in the field of bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases.
This press release may contain forward-looking statements, including express or implied statements regarding Magenta’s future expectations, plans and prospects, including projections regarding future revenues and financing performance, our long-term growth, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates and advancement of our preclinical programs, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” might,” “plan,” “potential,” “project,” “should,” target,” “will” or “would” and similar expressions constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. Although Magenta’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Magenta’s programs and operations are described in additional detail in its registration statement on Form S-1, its Quarterly Report on Form 10-Q and its other filings made with the Securities and Exchange Commission from time to time. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005450/en/
CONTACT: Magenta Therapeutics:
Manisha Pai, 857-242-1155
Vice President, Communications & Investor Relations
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS
SOURCE: Magenta Therapeutics
Copyright Business Wire 2018.
PUB: 09/24/2018 08:30 AM/DISC: 09/24/2018 08:30 AM